Ropeginterferon Alfa-2b Listed in NCCN Guidelines as A Preferred Polycythemia Vera Treatment
Updated National Comprehensive Cancer Network guidelines recommend ropeginterferon alfa-2b for patients with polycythemia vera.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.
Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia
In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.
Venetoclax/Obinutuzumab–Based Combinations Improve Undetectable MRD Rates in Fit Patients With CLL
Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations.
FDA Greenlights Avapritinib for Indolent Systemic Mastocytosis
The FDA has approved avapritinib for the treatment of patients with indolent systemic mastocytosis.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
